As­traZeneca’s Tagris­so hits the mark in late-stage lung can­cer main­te­nance study

As­traZeneca’s Tagris­so has im­proved sur­vival out­comes in a Phase III main­te­nance test for cer­tain lung can­cer pa­tients, paving the way for the drug to ex­pand its mar­ket by at least $500 mil­lion, ac­cord­ing to the com­pa­ny.

The LAU­RA tri­al en­rolled 216 sub­jects with un­re­sectable stage 3 epi­der­mal growth fac­tor re­cep­tor (EGFR) mu­tat­ed non-small cell lung can­cer whose dis­ease had not pro­gressed af­ter plat­inum-based chemora­dio­ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER